EA001915B1
(ru)
|
1996-10-18 |
2001-10-22 |
Вертекс Фармасьютикалз Инкорпорейтед |
Ингибиторы серин-протеаз, в частности ns3 протеазы вируса гепатита c (hvc)
|
GB9707659D0
(en)
*
|
1997-04-16 |
1997-06-04 |
Peptide Therapeutics Ltd |
Hepatitis C NS3 Protease inhibitors
|
US6767991B1
(en)
|
1997-08-11 |
2004-07-27 |
Boehringer Ingelheim (Canada) Ltd. |
Hepatitis C inhibitor peptides
|
ES2241157T3
(es)
*
|
1997-08-11 |
2005-10-16 |
Boehringer Ingelheim (Canada) Ltd. |
Peptidos inhibidores de la hepatitis c.
|
EP1012180B1
(de)
*
|
1997-08-11 |
2004-12-01 |
Boehringer Ingelheim (Canada) Ltd. |
Peptidanaloga mit inhibitorischer wirkung auf hepatitis c
|
GB9806815D0
(en)
|
1998-03-30 |
1998-05-27 |
Hoffmann La Roche |
Amino acid derivatives
|
JP4690545B2
(ja)
*
|
1998-03-31 |
2011-06-01 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
セリンプロテアーゼ、特にc型肝炎ウイルスns3プロテアーゼの阻害因子
|
GB9809664D0
(en)
*
|
1998-05-06 |
1998-07-01 |
Hoffmann La Roche |
a-Ketoamide derivatives
|
GB9812523D0
(en)
|
1998-06-10 |
1998-08-05 |
Angeletti P Ist Richerche Bio |
Peptide inhibitors of hepatitis c virus ns3 protease
|
US6323180B1
(en)
|
1998-08-10 |
2001-11-27 |
Boehringer Ingelheim (Canada) Ltd |
Hepatitis C inhibitor tri-peptides
|
AR022061A1
(es)
*
|
1998-08-10 |
2002-09-04 |
Boehringer Ingelheim Ca Ltd |
Peptidos inhibidores de la hepatitis c, una composicion farmaceutica que los contiene, el uso de los mismos para preparar una composicion farmaceutica, el uso de un producto intermedio para la preparacion de estos peptidos y un procedimiento para la preparacion de un peptido analogo de los mismos.
|
EP1159273A1
(de)
|
1999-03-02 |
2001-12-05 |
Boehringer Ingelheim Pharmaceuticals Inc. |
Verbindungen, verwendbar als reversible inhibitoren von cathepsin s
|
UA74546C2
(en)
*
|
1999-04-06 |
2006-01-16 |
Boehringer Ingelheim Ca Ltd |
Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
|
US6608027B1
(en)
|
1999-04-06 |
2003-08-19 |
Boehringer Ingelheim (Canada) Ltd |
Macrocyclic peptides active against the hepatitis C virus
|
CA2376965A1
(en)
*
|
1999-07-07 |
2001-01-11 |
Timothy Patrick Forsyth |
Peptide boronic acid inhibitors of hepatitis c virus protease
|
US7122627B2
(en)
|
1999-07-26 |
2006-10-17 |
Bristol-Myers Squibb Company |
Lactam inhibitors of Hepatitis C virus NS3 protease
|
CA2376961A1
(en)
*
|
1999-07-26 |
2001-02-01 |
Bristol-Myers Squibb Pharma Company |
Lactam inhibitors of hepatitis c virus ns3 protease
|
US6420364B1
(en)
|
1999-09-13 |
2002-07-16 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Compound useful as reversible inhibitors of cysteine proteases
|
US7026469B2
(en)
|
2000-10-19 |
2006-04-11 |
Wake Forest University School Of Medicine |
Compositions and methods of double-targeting virus infections and cancer cells
|
AU2055301A
(en)
|
1999-12-03 |
2001-06-12 |
Bristol-Myers Squibb Pharma Company |
Alpha-ketoamide inhibitors of hepatitis c virus ns3 protease
|
AU783095B2
(en)
*
|
1999-12-07 |
2005-09-22 |
Theravance Biopharma R&D Ip, Llc |
Carbamate derivatives having muscarinic receptor antagonist activity
|
US6699855B2
(en)
|
2000-02-29 |
2004-03-02 |
Bristol-Myers Squibb Company |
Inhibitors of hepatitis C virus NS3 protease
|
AU2006202124B2
(en)
*
|
2000-04-03 |
2010-01-21 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of Serine Proteases, Particularly Hepatitis C Virus NS3 Protease
|
ES2240446T3
(es)
*
|
2000-04-03 |
2005-10-16 |
Vertex Pharma |
Inhibidores de serina proteasas, particularmente la proteasa ns3 del virus de la hepatitis c.
|
WO2001077113A2
(en)
|
2000-04-05 |
2001-10-18 |
Schering Corporation |
Macrocyclic ns3-serine protease inhibitors of hepatitis c virus comprising n-cyclic p2 moieties
|
CN1935833A
(zh)
|
2000-04-19 |
2007-03-28 |
先灵公司 |
含有烷基和芳基丙氨酸p2部分的丙型肝炎病毒的大环ns3-丝氨酸蛋白酶抑制剂
|
PE20011350A1
(es)
|
2000-05-19 |
2002-01-15 |
Vertex Pharma |
PROFARMACO DE UN INHIBIDOR DE ENZIMA CONVERTIDORA DE INTERLEUCINA-1ß (ICE)
|
MY164523A
(en)
|
2000-05-23 |
2017-12-29 |
Univ Degli Studi Cagliari |
Methods and compositions for treating hepatitis c virus
|
CN1315862C
(zh)
|
2000-05-26 |
2007-05-16 |
艾登尼科斯(开曼)有限公司 |
处理黄病毒和瘟病毒的方法和组合物
|
US20020007324A1
(en)
*
|
2000-06-09 |
2002-01-17 |
Centner David J. |
System and method for effectively conducting transactions between buyers and suppliers
|
KR100939155B1
(ko)
*
|
2000-07-21 |
2010-01-28 |
쉐링 코포레이션 |
C형 간염 바이러스의 ns3-세린 프로테아제 억제제로서의신규한 펩티드
|
US7244721B2
(en)
*
|
2000-07-21 |
2007-07-17 |
Schering Corporation |
Peptides as NS3-serine protease inhibitors of hepatitis C virus
|
AR029851A1
(es)
|
2000-07-21 |
2003-07-16 |
Dendreon Corp |
Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c
|
HUP0303358A3
(en)
|
2000-07-21 |
2005-10-28 |
Schering Corp |
Novel peptides as ns3-serine protease inhibitors of hepatitis c virus and pharmaceutical compositions containing them
|
AR034127A1
(es)
|
2000-07-21 |
2004-02-04 |
Schering Corp |
Imidazolidinonas como inhibidores de ns3-serina proteasa del virus de hepatitis c, composicion farmaceutica, un metodo para su preparacion, y el uso de las mismas para la manufactura de un medicamento
|
SV2003000617A
(es)
*
|
2000-08-31 |
2003-01-13 |
Lilly Co Eli |
Inhibidores de la proteasa peptidomimetica ref. x-14912m
|
DK1326632T3
(da)
*
|
2000-10-12 |
2007-01-15 |
Viromics Gmbh |
Protease-inhibitorer til behandling af infektioner af hepatitisvirus
|
CA2426187C
(en)
|
2000-10-18 |
2011-08-16 |
Pharmasset Limited |
Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation
|
US6846806B2
(en)
|
2000-10-23 |
2005-01-25 |
Bristol-Myers Squibb Company |
Peptide inhibitors of Hepatitis C virus NS3 protein
|
EP1343807B1
(de)
*
|
2000-12-12 |
2009-04-29 |
Schering Corporation |
Diarylrest entfassende peptide als inhibitoren des ns-3 serinproteases von hepatitis c virus
|
US6653295B2
(en)
|
2000-12-13 |
2003-11-25 |
Bristol-Myers Squibb Company |
Inhibitors of hepatitis C virus NS3 protease
|
US6727366B2
(en)
|
2000-12-13 |
2004-04-27 |
Bristol-Myers Squibb Pharma Company |
Imidazolidinones and their related derivatives as hepatitis C virus NS3 protease inhibitors
|
SK286630B6
(sk)
|
2001-01-22 |
2009-02-05 |
Merck & Co., Inc. |
Nukleozidové deriváty, farmaceutický prostriedok s ich obsahom a ich použitie
|
WO2003006490A1
(en)
|
2001-07-11 |
2003-01-23 |
Vertex Pharmaceuticals Incorporated |
Bridged bicyclic serine protease inhibitors
|
CA2462163A1
(en)
|
2001-10-24 |
2003-05-01 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of serine protease, particularly hepatitis c virus ns3-ns4a protease, incorporating a fused ring system
|
MY151199A
(en)
*
|
2001-11-02 |
2014-04-30 |
Rigel Pharmaceuticals Inc |
Substituted diphenyl heterocycles useful for treating hcv infection
|
CA2473070C
(en)
|
2002-01-23 |
2009-10-13 |
Schering Corporation |
Proline compounds as ns3-serine protease inhibitors for use in treatment of hepatites c virus infection
|
US7119072B2
(en)
|
2002-01-30 |
2006-10-10 |
Boehringer Ingelheim (Canada) Ltd. |
Macrocyclic peptides active against the hepatitis C virus
|
US7091184B2
(en)
|
2002-02-01 |
2006-08-15 |
Boehringer Ingelheim International Gmbh |
Hepatitis C inhibitor tri-peptides
|
US6642204B2
(en)
|
2002-02-01 |
2003-11-04 |
Boehringer Ingelheim International Gmbh |
Hepatitis C inhibitor tri-peptides
|
AU2003223602B8
(en)
*
|
2002-04-11 |
2010-05-27 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of serine proteases, particularly hepatitis C virus NS3-NS4 protease
|
MY140680A
(en)
|
2002-05-20 |
2010-01-15 |
Bristol Myers Squibb Co |
Hepatitis c virus inhibitors
|
ES2361011T3
(es)
|
2002-05-20 |
2011-06-13 |
Bristol-Myers Squibb Company |
Inhibidores del virus de la hepatitis c.
|
ES2350201T3
(es)
|
2002-05-20 |
2011-01-20 |
Bristol-Myers Squibb Company |
Sulfamidas heterocíclicas como inhibidores del virus de la hepatitis c.
|
EP1505945B1
(de)
|
2002-05-20 |
2008-11-05 |
Bristol-Myers Squibb Company |
Substituierte cycloalkyl p1' hepatitis c virus inhibitoren
|
TW200500374A
(en)
|
2002-06-28 |
2005-01-01 |
Idenlx Cayman Ltd |
2' and 3' -nucleoside produrgs for treating flavivridae infections
|
WO2004026896A2
(en)
*
|
2002-09-23 |
2004-04-01 |
Medivir Ab |
Hcv ns-3 serine protease inhibitors
|
US20050075279A1
(en)
|
2002-10-25 |
2005-04-07 |
Boehringer Ingelheim International Gmbh |
Macrocyclic peptides active against the hepatitis C virus
|
CA2506129C
(en)
|
2002-11-15 |
2015-02-17 |
Idenix (Cayman) Limited |
2'-branched nucleosides and flaviviridae mutation
|
AU2011203054B2
(en)
*
|
2003-04-11 |
2012-04-26 |
Vertex Pharmaceuticals, Incorporated |
Inhibitors of Serine Proteases, Particularly HCV NS3-NS4A Protease
|
CN100453553C
(zh)
*
|
2003-04-11 |
2009-01-21 |
沃泰克斯药物股份有限公司 |
丝氨酸蛋白酶、特别是hcv ns3-ns4a蛋白酶的抑制剂
|
TW200510391A
(en)
*
|
2003-04-11 |
2005-03-16 |
Vertex Pharma |
Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
|
US7326790B2
(en)
|
2003-05-02 |
2008-02-05 |
Rigel Pharmaceuticals, Inc. |
Diphenylisoxazole compounds and hydro isomers thereof
|
DE602004010137T2
(de)
|
2003-05-21 |
2008-09-11 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Verbindungen als hepatitis c inhibitoren
|
SI2604620T1
(sl)
|
2003-05-30 |
2016-10-28 |
Gilead Pharmasset LLC c/o Gilead Sciences, Inc. |
Modificirani fluorirani nukleozidni analogi
|
CN102020700A
(zh)
|
2003-07-18 |
2011-04-20 |
沃泰克斯药物股份有限公司 |
丝氨酸蛋白酶抑制剂、特别是hcv ns3-ns4a蛋白酶抑制剂
|
ES2351603T3
(es)
|
2003-07-25 |
2011-02-08 |
Idenix Pharmaceuticals, Inc. |
Análogos de nucleósidos de purina para el tratamiento de enfermedades causadas por flaviridae incluyendo hepatitis c.
|
US7576206B2
(en)
|
2003-08-14 |
2009-08-18 |
Cephalon, Inc. |
Proteasome inhibitors and methods of using the same
|
US7223745B2
(en)
|
2003-08-14 |
2007-05-29 |
Cephalon, Inc. |
Proteasome inhibitors and methods of using the same
|
US7449447B2
(en)
|
2003-08-26 |
2008-11-11 |
Schering Corporation |
Peptidomimetic NS3-serine protease inhibitors of hepatitis C virus
|
TW201127828A
(en)
*
|
2003-09-05 |
2011-08-16 |
Vertex Pharma |
Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
|
WO2005028502A1
(en)
*
|
2003-09-18 |
2005-03-31 |
Vertex Pharmaceuticals, Incorporated |
Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
|
PE20050431A1
(es)
|
2003-09-22 |
2005-07-19 |
Boehringer Ingelheim Int |
Peptidos macrociclicos activos contra el virus de la hepatitis c
|
MXPA06003455A
(es)
|
2003-09-26 |
2006-05-31 |
Schering Corp |
Inhibidores macrociclicos de la serina proteasa ns3 del virus de la hepatitis c.
|
RU2006115558A
(ru)
*
|
2003-10-10 |
2007-11-20 |
Вертекс Фармасьютикалз Инкорпорейтед (Us) |
Ингибиторы сериновых протеаз, особенно hcv ns3-ns4a протеазы
|
MXPA06003963A
(es)
|
2003-10-14 |
2006-08-25 |
Intermune Inc |
Acidos carboxilicos macrociclicos y acilsulfonamidas como inhibidores de replicacion del hcv.
|
WO2005043118A2
(en)
|
2003-10-27 |
2005-05-12 |
Vertex Pharmaceuticals Incorporated |
Drug discovery method
|
JP4890254B2
(ja)
|
2003-10-27 |
2012-03-07 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
Hcvns3−ns4aプロテアーゼ耐性突然変異体
|
EP1944042A1
(de)
|
2003-10-27 |
2008-07-16 |
Vertex Pharmceuticals Incorporated |
Kombinationen für die HCV-Behandlung
|
US7132504B2
(en)
|
2003-11-12 |
2006-11-07 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7309708B2
(en)
|
2003-11-20 |
2007-12-18 |
Birstol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
EP1689770A1
(de)
|
2003-11-20 |
2006-08-16 |
Schering Corporation |
Depeptidisierte inhibitoren der hepatitis-c-virus-ns3-protease
|
US7135462B2
(en)
|
2003-11-20 |
2006-11-14 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
GB0500020D0
(en)
|
2005-01-04 |
2005-02-09 |
Novartis Ag |
Organic compounds
|
ES2358333T3
(es)
|
2004-01-21 |
2011-05-09 |
Boehringer Ingelheim International Gmbh |
Péptidos macrocíclicos con acción contra el virus de la hepatitis c.
|
JP4902361B2
(ja)
|
2004-01-30 |
2012-03-21 |
メディヴィル・アクチエボラーグ |
Hcvns−3セリンプロテアーゼインヒビター
|
CA2554999A1
(en)
*
|
2004-02-04 |
2005-08-25 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
|
SI1719773T1
(sl)
|
2004-02-24 |
2009-08-31 |
Japan Tobacco Inc |
Kondenzirane heterotetraciklične spojine in njihova uporaba kot inhibitorji polimeraze HCV
|
US20070049593A1
(en)
|
2004-02-24 |
2007-03-01 |
Japan Tobacco Inc. |
Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
|
US7186747B2
(en)
|
2004-02-27 |
2007-03-06 |
Schering Corporation |
Compounds as inhibitors of hepatitis C virus NS3 serine protease
|
KR101316137B1
(ko)
|
2004-02-27 |
2013-10-10 |
머크 샤프 앤드 돔 코포레이션 |
C형 간염 바이러스 ns3 세린 프로테아제의 억제제로서의황 화합물
|
CN1946691A
(zh)
|
2004-02-27 |
2007-04-11 |
先灵公司 |
作为丙型肝炎病毒ns3丝氨酸蛋白酶抑制剂的化合物
|
JP4745327B2
(ja)
|
2004-02-27 |
2011-08-10 |
シェーリング コーポレイション |
C型肝炎ウイルスns3プロテアーゼのインヒビター
|
US7816326B2
(en)
|
2004-02-27 |
2010-10-19 |
Schering Corporation |
Sulfur compounds as inhibitors of hepatitis C virus NS3 serine protease
|
CA2843066C
(en)
*
|
2004-03-12 |
2016-06-07 |
Vertex Pharmaceuticals Incorporated |
Processes and intermediates for the preparation of aspartic acetal caspase inhibitors
|
CN103554222A
(zh)
|
2004-04-15 |
2014-02-05 |
欧尼斯治疗公司 |
用于抑制蛋白酶体酶的化合物
|
US8198270B2
(en)
*
|
2004-04-15 |
2012-06-12 |
Onyx Therapeutics, Inc. |
Compounds for proteasome enzyme inhibition
|
PT2030981E
(pt)
*
|
2004-05-10 |
2014-10-14 |
Onyx Therapeutics Inc |
Compostos para inibição da enzima proteassoma
|
US7399749B2
(en)
|
2004-05-20 |
2008-07-15 |
Schering Corporation |
Substituted prolines as inhibitors of hepatitis C virus NS3 serine protease
|
KR20070034119A
(ko)
*
|
2004-07-16 |
2007-03-27 |
길리애드 사이언시즈, 인코포레이티드 |
항바이러스 화합물
|
CA2573346C
(en)
|
2004-07-20 |
2011-09-20 |
Boehringer Ingelheim International Gmbh |
Hepatitis c inhibitor peptide analogs
|
UY29016A1
(es)
|
2004-07-20 |
2006-02-24 |
Boehringer Ingelheim Int |
Analogos de dipeptidos inhibidores de la hepatitis c
|
MX2007001589A
(es)
*
|
2004-08-09 |
2007-08-02 |
Alios Biopharma Inc |
Variantes de polipeptido resistentes a proteasa, hiperglicosiladas sinteticas, formulaciones orales y metodos para utilizar las mismas.
|
US7597884B2
(en)
|
2004-08-09 |
2009-10-06 |
Alios Biopharma, Inc. |
Hyperglycosylated polypeptide variants and methods of use
|
US7550559B2
(en)
|
2004-08-27 |
2009-06-23 |
Schering Corporation |
Acylsulfonamide compounds as inhibitors of hepatitis C virus NS3 serine protease
|
EP3109244B1
(de)
|
2004-09-14 |
2019-03-06 |
Gilead Pharmasset LLC |
Herstellung von 2'fluor-2'-alkyl-substituierten oder von anderen wahlweise substituierten ribofuranosylpyrimidinen und -purinen und deren derivaten
|
KR20070061570A
(ko)
|
2004-10-01 |
2007-06-13 |
버텍스 파마슈티칼스 인코포레이티드 |
Hcv ns3-ns4a 프로테아제 저해
|
US7659263B2
(en)
|
2004-11-12 |
2010-02-09 |
Japan Tobacco Inc. |
Thienopyrrole compound and use thereof as HCV polymerase inhibitor
|
US7323447B2
(en)
|
2005-02-08 |
2008-01-29 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7468383B2
(en)
|
2005-02-11 |
2008-12-23 |
Cephalon, Inc. |
Proteasome inhibitors and methods of using the same
|
US7592336B2
(en)
|
2005-05-10 |
2009-09-22 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
KR20080016597A
(ko)
|
2005-05-13 |
2008-02-21 |
바이로켐 파마 인코포레이티드 |
플라비바이러스 감염의 예방 또는 치료용 화합물 및 그의예방 또는 치료 방법
|
EP1881828A4
(de)
*
|
2005-05-20 |
2009-06-03 |
Valeant Res & Dev |
Behandlung von hcv mittels subtherapeutischer dosen von ribavirin
|
US20060276404A1
(en)
*
|
2005-06-02 |
2006-12-07 |
Anima Ghosal |
Medicaments and methods combining a HCV protease inhibitor and an AKR competitor
|
NZ563361A
(en)
|
2005-06-02 |
2011-02-25 |
Schering Corp |
HCV protease inhibitors in combination with food
|
BRPI0610737A2
(pt)
|
2005-06-02 |
2010-07-20 |
Schering Corp |
formulações farmacêuticas e métodos de tratamento usando as mesmas
|
US20070237818A1
(en)
*
|
2005-06-02 |
2007-10-11 |
Malcolm Bruce A |
Controlled-release formulation of HCV protease inhibitor and methods using the same
|
ATE524183T1
(de)
|
2005-06-17 |
2011-09-15 |
Novartis Ag |
Verwendung von sanglifehrin bei der hcv-therapie
|
US7608592B2
(en)
*
|
2005-06-30 |
2009-10-27 |
Virobay, Inc. |
HCV inhibitors
|
US7601686B2
(en)
|
2005-07-11 |
2009-10-13 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
MX2008001166A
(es)
|
2005-07-25 |
2008-03-18 |
Intermune Inc |
Nuevos inhibidores macrociclicos de la replicacion del virus de hepatitis c.
|
CN101282978B
(zh)
|
2005-07-29 |
2012-07-11 |
泰博特克药品有限公司 |
丙型肝炎病毒的大环抑制剂
|
EP1919899B1
(de)
|
2005-07-29 |
2011-01-19 |
Tibotec Pharmaceuticals |
Makrocyclische inhibitoren des hepatitis-c-virus
|
PE20070210A1
(es)
|
2005-07-29 |
2007-04-16 |
Tibotec Pharm Ltd |
Compuestos macrociclicos como inhibidores del virus de hepatitis c
|
BRPI0614621A2
(pt)
|
2005-07-29 |
2011-04-12 |
Tibotec Pharm Ltd |
inibidores macrocìclicos de vìrus da hepatite c
|
PE20070211A1
(es)
|
2005-07-29 |
2007-05-12 |
Medivir Ab |
Compuestos macrociclicos como inhibidores del virus de hepatitis c
|
AU2006274861B2
(en)
|
2005-07-29 |
2012-11-08 |
Medivir Ab |
Macrocyclic inhibitors of hepatitis C virus
|
RU2437886C2
(ru)
|
2005-07-29 |
2011-12-27 |
Тиботек Фармасьютикалз Лтд. |
Макроциклические ингибиторы вируса гепатита с
|
JO2768B1
(en)
|
2005-07-29 |
2014-03-15 |
تيبوتيك فارماسيوتيكالز ليمتد |
Large cyclic inhibitors of hepatitis C virus
|
EP1913015B1
(de)
|
2005-07-29 |
2013-12-11 |
Janssen R&D Ireland |
Makrozyklische hemmer des hepatitis-c-virus
|
JP2009503084A
(ja)
*
|
2005-08-01 |
2009-01-29 |
フェノミックス コーポレーション |
C型肝炎セリンプロテアーゼ阻害剤およびその使用
|
EP2402331A1
(de)
|
2005-08-02 |
2012-01-04 |
Vertex Pharmaceuticals Incorporated |
Serinprotease-Hemmer
|
US8399615B2
(en)
|
2005-08-19 |
2013-03-19 |
Vertex Pharmaceuticals Incorporated |
Processes and intermediates
|
PT1934179E
(pt)
*
|
2005-08-19 |
2010-07-12 |
Vertex Pharma |
PROCESSOS E INTERMEDIáRIOS
|
US7964624B1
(en)
|
2005-08-26 |
2011-06-21 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of serine proteases
|
AR055395A1
(es)
|
2005-08-26 |
2007-08-22 |
Vertex Pharma |
Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
|
ES2356776T3
(es)
|
2005-10-11 |
2011-04-13 |
Intermune, Inc. |
Compuestos y métodos para inhibir la replicación del virus de la hepatitis.
|
BRPI0617271A2
(pt)
*
|
2005-10-11 |
2011-07-19 |
Intermune Inc |
inibidores de replicação viral
|
US7772183B2
(en)
|
2005-10-12 |
2010-08-10 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7741281B2
(en)
|
2005-11-03 |
2010-06-22 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
KR101274417B1
(ko)
|
2005-11-09 |
2013-06-17 |
프로테올릭스, 인코퍼레이티드 |
효소 저해를 위한 화합물
|
NZ568324A
(en)
|
2005-11-11 |
2012-01-12 |
Vertex Pharma |
Hepatitis C virus variants
|
US7705138B2
(en)
|
2005-11-11 |
2010-04-27 |
Vertex Pharmaceuticals Incorporated |
Hepatitis C virus variants
|
AU2006332945C1
(en)
|
2005-12-23 |
2013-02-28 |
Wyeth |
Modified lysine-mimetic compounds
|
US20090304631A1
(en)
*
|
2006-01-27 |
2009-12-10 |
David Alan Campbell |
Hepatitis c serine protease inhibitors and uses therefor
|
JP2009526070A
(ja)
*
|
2006-02-09 |
2009-07-16 |
シェーリング コーポレイション |
Hcvプロテアーゼ阻害薬とhcvポリメラーゼ阻害薬との組み合わせ、ならびにそれらに関連する処置の方法
|
EP1991229A2
(de)
|
2006-02-27 |
2008-11-19 |
Vertex Pharmaceuticals Incorporated |
Kokristalle und pharmazeutische zusammensetzungen damit
|
NZ571280A
(en)
*
|
2006-03-16 |
2011-10-28 |
Vertex Pharma |
Deuterated hepatitis C protease inhibitors
|
MX2008013119A
(es)
|
2006-04-11 |
2008-10-21 |
Novartis Ag |
Inhibidores de hcv/vih y sus usos.
|
US8017612B2
(en)
|
2006-04-18 |
2011-09-13 |
Japan Tobacco Inc. |
Piperazine compound and use thereof as a HCV polymerase inhibitor
|
AU2007253819B2
(en)
|
2006-05-23 |
2011-02-17 |
Irm Llc |
Compounds and compositions as channel activating protease inhibitors
|
CA2657213C
(en)
|
2006-06-19 |
2017-01-03 |
Proteolix, Inc. |
Peptide epoxyketones for proteasome inhibition
|
WO2008008776A2
(en)
|
2006-07-11 |
2008-01-17 |
Bristol-Myers Squibb Company |
Hepatitis c virus inhibitors
|
EP1886685A1
(de)
|
2006-08-11 |
2008-02-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methoden, Verwendungen und Zusammensetzungen zur Modulation der Replikation von HCV durch Aktivierung oder Hemmung des Farnesoid X Rezeptors
|
US20080131398A1
(en)
*
|
2006-08-21 |
2008-06-05 |
United Therapeutics Corporation |
Combination therapy for treatment of viral infections
|
EP2057278A2
(de)
*
|
2006-08-28 |
2009-05-13 |
Vertex Pharmceuticals Incorporated |
Verfahren zur identifikation von protease-hemmern
|
US8343477B2
(en)
|
2006-11-01 |
2013-01-01 |
Bristol-Myers Squibb Company |
Inhibitors of hepatitis C virus
|
US7772180B2
(en)
|
2006-11-09 |
2010-08-10 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
PL2104674T3
(pl)
|
2006-11-15 |
2013-12-31 |
Vertex Pharmaceuticals Canada Incorporated |
Analogi tiofenu do leczenia lub zapobiegania zakażeniom flawiwirusowym
|
US7763584B2
(en)
|
2006-11-16 |
2010-07-27 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US8003604B2
(en)
|
2006-11-16 |
2011-08-23 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7888464B2
(en)
|
2006-11-16 |
2011-02-15 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
JP2010512317A
(ja)
|
2006-12-07 |
2010-04-22 |
シェーリング コーポレイション |
pH感受性マトリクス処方物
|
EP2074087A2
(de)
|
2006-12-21 |
2009-07-01 |
Wyeth |
Synthese von pyrrolidinverbindungen
|
WO2008136815A2
(en)
|
2006-12-22 |
2008-11-13 |
Schering Corporation |
5, 6-ring annulated indole derivatives and use thereof
|
JP5211068B2
(ja)
|
2006-12-22 |
2013-06-12 |
メルク・シャープ・アンド・ドーム・コーポレーション |
Hcvおよび関連するウイルス疾患の治療または予防のための4,5−環インドール誘導体
|
KR20090094154A
(ko)
|
2006-12-22 |
2009-09-03 |
쉐링 코포레이션 |
Hcv 및 관련 바이러스 감염을 치료 또는 예방하기 위한 4,5-환 환상 인돌 유도체
|
CN101641349A
(zh)
|
2007-02-08 |
2010-02-03 |
泰博特克药品有限公司 |
嘧啶取代的大环抑制剂
|
EA016327B1
(ru)
*
|
2007-02-09 |
2012-04-30 |
Айрм Ллк |
Соединения и композиции в качестве ингибиторов протеазы, активирующей каналы
|
NZ579295A
(en)
|
2007-02-27 |
2012-03-30 |
Vertex Pharma |
Inhibitors of serine proteases
|
AU2008219607B2
(en)
*
|
2007-02-27 |
2013-09-12 |
Vertex Pharmaceuticals Incorporated |
Co-crystals and pharmaceutical compositions comprising the same
|
WO2008106167A1
(en)
*
|
2007-02-28 |
2008-09-04 |
Conatus Pharmaceuticals, Inc. |
Combination therapy comprising matrix metalloproteinase inhibitors and caspase inhibitors for the treatment of liver diseases
|
ATE525068T1
(de)
|
2007-02-28 |
2011-10-15 |
Conatus Pharmaceuticals Inc |
Verfahren zur behandlung von chronischer viraler hepatitis c mithilfe von ro 113-0830
|
US7964580B2
(en)
|
2007-03-30 |
2011-06-21 |
Pharmasset, Inc. |
Nucleoside phosphoramidate prodrugs
|
CA2686051A1
(en)
|
2007-05-04 |
2008-11-13 |
Vertex Pharmaceuticals Incorporated |
Combination therapy for the treatment of hcv infection
|
BRPI0813733A2
(pt)
|
2007-06-29 |
2019-11-05 |
Gilead Sciences Inc |
composto com atividade inibidora de hcv, sua composição farmacêutica e seu uso.
|
UA98494C2
(uk)
|
2007-06-29 |
2012-05-25 |
Гіліад Сайєнсіз, Інк. |
Противірусні сполуки
|
AU2008295485B2
(en)
|
2007-08-29 |
2013-09-05 |
Merck Sharp & Dohme Corp. |
2,3-substituted azaindole derivatives for treating viral infections
|
MX2010002317A
(es)
|
2007-08-29 |
2010-03-22 |
Schering Corp |
Derivados de indol sustituidos y metodos para su utilizacion.
|
CA2697375A1
(en)
|
2007-08-29 |
2009-03-12 |
Schering Corporation |
2, 3-substituted indole derivatives for treating viral infections
|
ATE530546T1
(de)
*
|
2007-08-30 |
2011-11-15 |
Vertex Pharma |
Kokristalle und pharmazeutische zusammensetzungen damit
|
GB0718575D0
(en)
|
2007-09-24 |
2007-10-31 |
Angeletti P Ist Richerche Bio |
Nucleoside derivatives as inhibitors of viral polymerases
|
MY173938A
(en)
*
|
2007-10-04 |
2020-02-27 |
Onyx Therapeutics Inc |
Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides
|
EP2222660B1
(de)
|
2007-11-16 |
2014-03-26 |
Merck Sharp & Dohme Corp. |
3-heterocyclylsubstituierte indolderivate und verfahren zu deren anwendung
|
JP5416708B2
(ja)
|
2007-11-16 |
2014-02-12 |
メルク・シャープ・アンド・ドーム・コーポレーション |
3−アミノスルホニル置換インドール誘導体およびそれらの使用方法
|
US8202996B2
(en)
|
2007-12-21 |
2012-06-19 |
Bristol-Myers Squibb Company |
Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
|
TW200936131A
(en)
|
2008-02-04 |
2009-09-01 |
Idenix Pharmaceuticals Inc |
Macrocyclic serine protease inhibitors
|
TW200946541A
(en)
|
2008-03-27 |
2009-11-16 |
Idenix Pharmaceuticals Inc |
Solid forms of an anti-HIV phosphoindole compound
|
US8163921B2
(en)
|
2008-04-16 |
2012-04-24 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
JP5529120B2
(ja)
|
2008-05-29 |
2014-06-25 |
ブリストル−マイヤーズ スクイブ カンパニー |
C型肝炎ウイルス阻害剤
|
US7964560B2
(en)
|
2008-05-29 |
2011-06-21 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
AR072088A1
(es)
|
2008-06-13 |
2010-08-04 |
Schering Corp |
Derivados de indol triciclicos y sus metodos de uso
|
ES2458358T3
(es)
|
2008-07-02 |
2014-05-05 |
Idenix Pharmaceuticals, Inc. |
Compuestos y composiciones farmacéuticas para el tratamiento de infecciones víricas
|
EP2326627A1
(de)
|
2008-08-20 |
2011-06-01 |
Schering Corporation |
Substituierte pyridin- und pyrimidinderivate und ihre verwendung bei der behandlung von virusinfektionen
|
WO2010022128A1
(en)
|
2008-08-20 |
2010-02-25 |
Schering Corporation |
Ethenyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
|
EP2331511A1
(de)
|
2008-08-20 |
2011-06-15 |
Schering Corporation |
Ethinylsubstituierte pyridin- und pyrimidinderivate und ihre verwendung bei der behandlung von virusinfektionen
|
AU2009282572B2
(en)
|
2008-08-20 |
2014-09-11 |
Merck Sharp & Dohme Corp. |
Azo-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
|
US8207341B2
(en)
|
2008-09-04 |
2012-06-26 |
Bristol-Myers Squibb Company |
Process or synthesizing substituted isoquinolines
|
US8563505B2
(en)
|
2008-09-29 |
2013-10-22 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US8044087B2
(en)
|
2008-09-29 |
2011-10-25 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
EP3025727A1
(de)
|
2008-10-02 |
2016-06-01 |
The J. David Gladstone Institutes |
Verfahren zur behandlung von lebererkrankungen
|
PE20120059A1
(es)
|
2008-10-21 |
2012-02-27 |
Onyx Therapeutics Inc |
Combinaciones farmaceuticas con epoxicetonas peptidicas
|
WO2010065674A1
(en)
|
2008-12-03 |
2010-06-10 |
Presidio Pharmaceuticals, Inc. |
Inhibitors of hcv ns5a
|
US8865756B2
(en)
|
2008-12-03 |
2014-10-21 |
Presidio Pharmaceuticals, Inc. |
Inhibitors of HCV NS5A
|
US8283310B2
(en)
|
2008-12-15 |
2012-10-09 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US8589372B2
(en)
|
2008-12-16 |
2013-11-19 |
Clinton A. Krislov |
Method and system for automated document registration with cloud computing
|
US8914351B2
(en)
|
2008-12-16 |
2014-12-16 |
Clinton A. Krislov |
Method and system for secure automated document registration from social media networks
|
JP2012512878A
(ja)
*
|
2008-12-19 |
2012-06-07 |
ギリアード サイエンシーズ, インコーポレイテッド |
Hcvns3プロテアーゼインヒビター
|
KR20110104074A
(ko)
|
2008-12-23 |
2011-09-21 |
파마셋 인코포레이티드 |
퓨린 뉴클레오시드의 합성
|
AU2009329917B2
(en)
|
2008-12-23 |
2016-03-31 |
Gilead Pharmasset Llc |
Nucleoside analogs
|
EP2376088B1
(de)
|
2008-12-23 |
2017-02-22 |
Gilead Pharmasset LLC |
6-O-Substituierte-2-Amino-Purin-Nukleosid-Phosphoramidate
|
US8102720B2
(en)
*
|
2009-02-02 |
2012-01-24 |
Qualcomm Incorporated |
System and method of pulse generation
|
US8193372B2
(en)
|
2009-03-04 |
2012-06-05 |
Idenix Pharmaceuticals, Inc. |
Phosphothiophene and phosphothiazole HCV polymerase inhibitors
|
US8975247B2
(en)
|
2009-03-18 |
2015-03-10 |
The Board Of Trustees Of The Leland Stanford Junion University |
Methods and compositions of treating a flaviviridae family viral infection
|
TWI504598B
(zh)
|
2009-03-20 |
2015-10-21 |
Onyx Therapeutics Inc |
結晶性三肽環氧酮蛋白酶抑制劑
|
MX2011010132A
(es)
|
2009-03-27 |
2011-10-14 |
Presidio Pharmaceuticals Inc |
Inhibidores de anillo fusionado de hepatitis c.
|
EP2416765B1
(de)
|
2009-04-06 |
2016-03-30 |
PTC Therapeutics, Inc. |
Kombinationen von hcv-inhibitor und therapeutischen mitteln
|
US9198907B2
(en)
|
2009-04-06 |
2015-12-01 |
Ptc Therapeutics, Inc. |
Combinations of a HCV inhibitor such as bicyclic pyrrole derivatives and a therapeutic agent
|
EP2417134B1
(de)
|
2009-04-08 |
2017-05-17 |
Idenix Pharmaceuticals LLC. |
Macrocyclische serinproteaseinhibitoren
|
US8512690B2
(en)
|
2009-04-10 |
2013-08-20 |
Novartis Ag |
Derivatised proline containing peptide compounds as protease inhibitors
|
US20110182850A1
(en)
|
2009-04-10 |
2011-07-28 |
Trixi Brandl |
Organic compounds and their uses
|
TWI583692B
(zh)
|
2009-05-20 |
2017-05-21 |
基利法瑪席特有限責任公司 |
核苷磷醯胺
|
US8618076B2
(en)
|
2009-05-20 |
2013-12-31 |
Gilead Pharmasset Llc |
Nucleoside phosphoramidates
|
WO2010138791A1
(en)
|
2009-05-29 |
2010-12-02 |
Schering Corporation |
Antiviral compounds composed of three linked aryl moieties to treat diseases such as hepatitis c
|
CA2769652A1
(en)
|
2009-08-05 |
2011-02-10 |
Idenix Pharmaceuticals, Inc. |
Macrocyclic serine protease inhibitors useful against viral infections, particularly hcv
|
HUE030402T2
(en)
|
2009-09-15 |
2017-05-29 |
Taigen Biotechnology Co Ltd |
HCV protease inhibitors
|
WO2011060179A1
(en)
|
2009-11-13 |
2011-05-19 |
Onyx Therapeutics, Inc |
Use of peptide epoxyketones for metastasis suppression
|
WO2011063076A1
(en)
|
2009-11-19 |
2011-05-26 |
Itherx Pharmaceuticals, Inc. |
Methods of treating hepatitis c virus with oxoacetamide compounds
|
US20120276047A1
(en)
|
2009-11-25 |
2012-11-01 |
Rosenblum Stuart B |
Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases
|
EP2504329A1
(de)
|
2009-11-25 |
2012-10-03 |
Vertex Pharmaceuticals Incorporated |
5-alkynyl-thiophen-2-carbonsäurederivate und ihre verwendung zur behandlung oder prävention von flavivirus-infektionen
|
MX2012006877A
(es)
|
2009-12-18 |
2012-08-31 |
Idenix Pharmaceuticals Inc |
Inhibidores de virus de hepatitis c de arileno o heteroarileno 5, 5 - fusionado.
|
CA2785488A1
(en)
|
2009-12-22 |
2011-07-21 |
Merck Sharp & Dohme Corp. |
Fused tricyclic compounds and methods of use thereof for the treatment of viral diseases
|
EP2516449A1
(de)
|
2009-12-22 |
2012-10-31 |
Cephalon, Inc. |
Proteasehemmer und verfahren zu ihrer herstellung, reinigung und verwendung
|
MX2012007420A
(es)
|
2009-12-24 |
2012-07-23 |
Vertex Pharma |
Analogos para el tratamiento o prevencion de infecciones de flavivirus.
|
US8653025B2
(en)
|
2010-01-27 |
2014-02-18 |
AB Pharma Ltd. |
Polyheterocyclic compounds highly potent as HCV inhibitors
|
WO2011103441A1
(en)
|
2010-02-18 |
2011-08-25 |
Schering Corporation |
Substituted pyridine and pyrimidine derivatives and their use in treating viral infections
|
MA34133B1
(fr)
|
2010-03-01 |
2013-04-03 |
Onyx Therapeutics Inc |
Composes pour inhibiteurs de l'immunoproteasome
|
WO2011112516A1
(en)
|
2010-03-08 |
2011-09-15 |
Ico Therapeutics Inc. |
Treating and preventing hepatitis c virus infection using c-raf kinase antisense oligonucleotides
|
KR20130008040A
(ko)
|
2010-03-09 |
2013-01-21 |
머크 샤프 앤드 돔 코포레이션 |
융합된 트리시클릭 실릴 화합물 및 바이러스성 질환의 치료를 위한 그의 사용 방법
|
EP2550268A1
(de)
|
2010-03-24 |
2013-01-30 |
Vertex Pharmaceuticals Incorporated |
Analoga zur behandlung oder vorbeugung von flavivirus-infektionen
|
MX2012010918A
(es)
|
2010-03-24 |
2013-01-18 |
Vertex Pharma |
Analogos para el tratamiento o prevencion de infecciones por flavivirus.
|
JP2013522377A
(ja)
|
2010-03-24 |
2013-06-13 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
フラビウイルス感染を処置または予防するためのアナログ
|
EP2550262A1
(de)
|
2010-03-24 |
2013-01-30 |
Vertex Pharmaceuticals Incorporated |
Analoga zur behandlung oder vorbeugung von flavivirus-infektionen
|
HUE034239T2
(en)
|
2010-03-31 |
2018-02-28 |
Gilead Pharmasset Llc |
Method for Crystallization of (S) -isopropyl 2 - (((S) (perfluorophenoxy) (phenoxy) phosphoryl) amino) propanoate \ t
|
US8680071B2
(en)
|
2010-04-01 |
2014-03-25 |
Idenix Pharmaceuticals, Inc. |
Compounds and pharmaceutical compositions for the treatment of viral infections
|
AU2011245630B2
(en)
|
2010-04-07 |
2014-07-03 |
Onyx Therapeutics, Inc. |
Crystalline peptide epoxyketone immunoproteasome inhibitor
|
CA2800509A1
(en)
|
2010-05-24 |
2011-12-01 |
Presidio Pharmaceuticals, Inc. |
Inhibitors of hcv ns5a
|
WO2011156545A1
(en)
|
2010-06-09 |
2011-12-15 |
Vertex Pharmaceuticals Incorporated |
Viral dynamic model for hcv combination therapy
|
WO2011159826A2
(en)
|
2010-06-15 |
2011-12-22 |
Vertex Pharmaceuticals Incorporated |
Hcv ns5b protease mutants
|
MX2012014918A
(es)
|
2010-06-28 |
2013-04-08 |
Vertex Pharma |
Compuestos y metodos para tratamiento o prevencion de infecciones por flavivirus.
|
JP2013531011A
(ja)
|
2010-06-28 |
2013-08-01 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
フラビウイルス感染の処置または予防のための化合物および方法
|
WO2012006070A1
(en)
|
2010-06-28 |
2012-01-12 |
Vertex Pharmaceuticals Incorporated |
Compounds and methods for the treatment or prevention of flavivirus infections
|
EP2598149A4
(de)
|
2010-07-26 |
2014-09-10 |
Merck Sharp & Dohme |
Substituierte biphenylenverbindungen und verfahren zu ihrer verwendung zur behandlung von virenerkrankungen
|
WO2012020036A1
(en)
|
2010-08-13 |
2012-02-16 |
F. Hoffmann-La Roche Ag |
Hepatitis c virus inhibitors
|
MX2013001869A
(es)
|
2010-08-17 |
2013-06-28 |
Vertex Pharma |
Compuestos y metodos para el tratamiento o prevencion de infecciones virales por flaviviridae.
|
WO2012050848A1
(en)
|
2010-09-29 |
2012-04-19 |
Schering Corporation |
Fused tetracycle derivatives and methods of use thereof for the treatment of viral diseases
|
AU2011311880B2
(en)
|
2010-10-08 |
2014-07-24 |
Novartis Ag |
Vitamin E formulations of sulfamide NS3 inhibitors
|
CA2815855C
(en)
|
2010-11-01 |
2016-02-02 |
Rfs Pharma, Llc |
Novel specific hcv ns3 protease inhibitors
|
TW201242974A
(en)
|
2010-11-30 |
2012-11-01 |
Gilead Pharmasset Llc |
Compounds
|
US9353100B2
(en)
|
2011-02-10 |
2016-05-31 |
Idenix Pharmaceuticals Llc |
Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections
|
WO2012107589A1
(en)
|
2011-02-11 |
2012-08-16 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment and prevention of hcv infections
|
WO2012123298A1
(en)
|
2011-03-11 |
2012-09-20 |
F. Hoffmann-La Roche Ag |
Antiviral compounds
|
US20120252721A1
(en)
|
2011-03-31 |
2012-10-04 |
Idenix Pharmaceuticals, Inc. |
Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
|
JP2014514295A
(ja)
|
2011-03-31 |
2014-06-19 |
アイディニックス ファーマシューティカルズ インコーポレイテッド |
ウイルス感染の治療のための化合物および薬学的組成物
|
WO2012142075A1
(en)
|
2011-04-13 |
2012-10-18 |
Merck Sharp & Dohme Corp. |
2'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
|
US8957203B2
(en)
|
2011-05-05 |
2015-02-17 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US10501493B2
(en)
|
2011-05-27 |
2019-12-10 |
Rqx Pharmaceuticals, Inc. |
Broad spectrum antibiotics
|
US8691757B2
(en)
|
2011-06-15 |
2014-04-08 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
CA2857705A1
(en)
|
2011-06-16 |
2012-12-20 |
AB Pharma Ltd. |
Macrocyclic heterocyclic compounds for inhibiting hepatitis c virus and preparation and use thereof
|
CN103732242A
(zh)
|
2011-06-23 |
2014-04-16 |
迪格纳生物技术公司 |
用与IFN-α2b组合的IFN-α5在患者群体中治疗慢性丙型肝炎
|
US20120328565A1
(en)
|
2011-06-24 |
2012-12-27 |
Brinkman John A |
Antiviral compounds
|
CN102807607B
(zh)
*
|
2011-07-22 |
2013-10-23 |
爱博新药研发(上海)有限公司 |
抑制丙肝病毒的稠环杂环类化合物、其中间体及其应用
|
AR087345A1
(es)
|
2011-07-26 |
2014-03-19 |
Vertex Pharma |
Metodos para la preparacion de compuestos de tiofeno
|
WO2013016499A1
(en)
|
2011-07-26 |
2013-01-31 |
Vertex Pharmaceuticals Incorporated |
Methods for preparation of thiophene compounds
|
WO2013033900A1
(en)
|
2011-09-08 |
2013-03-14 |
Merck Sharp & Dohme Corp. |
Tetracyclic heterocycle compounds and methods of use thereof for the treatment of viral diseases
|
WO2013033899A1
(en)
|
2011-09-08 |
2013-03-14 |
Merck Sharp & Dohme Corp. |
Substituted benzofuran compounds and methods of use thereof for the treatment of viral diseases
|
WO2013033901A1
(en)
|
2011-09-08 |
2013-03-14 |
Merck Sharp & Dohme Corp. |
Heterocyclic-substituted benzofuran derivatives and methods of use thereof for the treatment of viral diseases
|
JP2014526474A
(ja)
|
2011-09-12 |
2014-10-06 |
アイディニックス ファーマシューティカルズ インコーポレイテッド |
ウイルス感染の治療のための化合物および薬学的組成物
|
EP2755983B1
(de)
|
2011-09-12 |
2017-03-15 |
Idenix Pharmaceuticals LLC. |
Substituierte carbonyloxymethylphosphoramidatverbindungen und pharmazeutische zusammensetzungen zur behandlung von virusinfektionen
|
WO2013039876A1
(en)
|
2011-09-14 |
2013-03-21 |
Merck Sharp & Dohme Corp. |
Silyl-containing heterocyclic compounds and methods of use thereof for the treatment of viral diseases
|
JP5808496B2
(ja)
|
2011-10-10 |
2015-11-10 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
抗ウイルス化合物
|
WO2013056046A1
(en)
|
2011-10-14 |
2013-04-18 |
Idenix Pharmaceuticals, Inc. |
Substituted 3',5'-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections
|
US20130123276A1
(en)
|
2011-11-14 |
2013-05-16 |
Sven Ruf |
Use of telaprevir and related compounds in atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases
|
US8889159B2
(en)
|
2011-11-29 |
2014-11-18 |
Gilead Pharmasset Llc |
Compositions and methods for treating hepatitis C virus
|
EP3750544A3
(de)
|
2011-11-30 |
2021-03-24 |
Emory University |
Jak-hemmer zur vorbeugung oder behandlung der viralen infektion
|
US9364484B2
(en)
|
2011-12-06 |
2016-06-14 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods and compositions for treating viral diseases
|
KR20140104030A
(ko)
|
2011-12-16 |
2014-08-27 |
에프. 호프만-라 로슈 아게 |
Hcv ns5a의 억제제
|
MX350809B
(es)
|
2011-12-20 |
2017-09-20 |
Riboscience Llc |
Derivados nucleósidos con sustitución 2',4'-difluoro-2'-metilo como inhibidores de la replicación del arn del vhc.
|
MX350810B
(es)
|
2011-12-20 |
2017-09-20 |
Riboscience Llc |
Derivados de los nucleosidos sustituidos en 4 '-azido, 3 '-fluoro como inhibidores de la replicacion del rna del vhc.
|
US8809354B2
(en)
|
2011-12-31 |
2014-08-19 |
Sheikh Riazuddin |
3-amino-2-(4-nitrophenyl)-4-(3H)-quinazolinone or derivatives thereof for treating or preventing antiviral infections
|
CN104039774A
(zh)
|
2012-01-12 |
2014-09-10 |
Rfs制药公司 |
Hcv ns3蛋白酶抑制剂
|
US20130217644A1
(en)
|
2012-02-13 |
2013-08-22 |
Idenix Pharmaceuticals, Inc. |
Pharmaceutical Compositions of 2'-C-Methyl-Guanosine, 5'-[2[(3-Hydroxy-2,2-Dimethyl-1-Oxopropyl)Thio]Ethyl N-(Phenylmethyl)Phosphoramidate]
|
CA2864669A1
(en)
*
|
2012-02-16 |
2013-08-22 |
Rqx Pharmaceuticals, Inc. |
Linear peptide antibiotics
|
CN104185624B
(zh)
|
2012-02-24 |
2016-10-12 |
弗·哈夫曼-拉罗切有限公司 |
抗病毒化合物
|
NZ630805A
(en)
|
2012-03-22 |
2016-01-29 |
Alios Biopharma Inc |
Pharmaceutical combinations comprising a thionucleotide analog
|
US9109001B2
(en)
|
2012-05-22 |
2015-08-18 |
Idenix Pharmaceuticals, Inc. |
3′,5′-cyclic phosphoramidate prodrugs for HCV infection
|
EP2852603B1
(de)
|
2012-05-22 |
2021-05-12 |
Idenix Pharmaceuticals LLC |
D-aminosäure-verbindungen gegen lebererkrankungen
|
US9296778B2
(en)
|
2012-05-22 |
2016-03-29 |
Idenix Pharmaceuticals, Inc. |
3′,5′-cyclic phosphate prodrugs for HCV infection
|
US20140010783A1
(en)
|
2012-07-06 |
2014-01-09 |
Hoffmann-La Roche Inc. |
Antiviral compounds
|
WO2014011695A2
(en)
|
2012-07-09 |
2014-01-16 |
Onyx Therapeutics, Inc. |
Prodrugs of peptide epoxy ketone protease inhibitors
|
WO2014053533A1
(en)
|
2012-10-05 |
2014-04-10 |
Sanofi |
Use of substituted 3-heteroaroylamino-propionic acid derivatives as pharmaceuticals for prevention/treatment of atrial fibrillation
|
SG11201502750UA
(en)
|
2012-10-08 |
2015-06-29 |
Idenix Pharmaceuticals Inc |
2'-chloro nucleoside analogs for hcv infection
|
BR112015007879A2
(pt)
|
2012-10-19 |
2017-07-04 |
Bristol Myers Squibb Co |
inibidores do vírus da hepatite c
|
US20140112886A1
(en)
|
2012-10-19 |
2014-04-24 |
Idenix Pharmaceuticals, Inc. |
Dinucleotide compounds for hcv infection
|
WO2014066239A1
(en)
|
2012-10-22 |
2014-05-01 |
Idenix Pharmaceuticals, Inc. |
2',4'-bridged nucleosides for hcv infection
|
US10260089B2
(en)
|
2012-10-29 |
2019-04-16 |
The Research Foundation Of The State University Of New York |
Compositions and methods for recognition of RNA using triple helical peptide nucleic acids
|
US9598433B2
(en)
|
2012-11-02 |
2017-03-21 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US9334279B2
(en)
|
2012-11-02 |
2016-05-10 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US9643999B2
(en)
|
2012-11-02 |
2017-05-09 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
EP2914614B1
(de)
|
2012-11-05 |
2017-08-16 |
Bristol-Myers Squibb Company |
Inhibitoren des hepatitis-c-virus
|
US20140140951A1
(en)
|
2012-11-14 |
2014-05-22 |
Idenix Pharmaceuticals, Inc. |
D-Alanine Ester of Rp-Nucleoside Analog
|
WO2014078436A1
(en)
|
2012-11-14 |
2014-05-22 |
Idenix Pharmaceuticals, Inc. |
D-alanine ester of sp-nucleoside analog
|
WO2014099941A1
(en)
|
2012-12-19 |
2014-06-26 |
Idenix Pharmaceuticals, Inc. |
4'-fluoro nucleosides for the treatment of hcv
|
BR112015017414A2
(pt)
|
2013-01-23 |
2017-07-11 |
Hoffmann La Roche |
derivados de triazol antivirais
|
US20150065439A1
(en)
|
2013-02-28 |
2015-03-05 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical compositions
|
WO2014137930A1
(en)
|
2013-03-04 |
2014-09-12 |
Idenix Pharmaceuticals, Inc. |
Thiophosphate nucleosides for the treatment of hcv
|
WO2014137926A1
(en)
|
2013-03-04 |
2014-09-12 |
Idenix Pharmaceuticals, Inc. |
3'-deoxy nucleosides for the treatment of hcv
|
KR20150114566A
(ko)
|
2013-03-05 |
2015-10-12 |
에프. 호프만-라 로슈 아게 |
항바이러스 화합물
|
US9580463B2
(en)
|
2013-03-07 |
2017-02-28 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US9187515B2
(en)
|
2013-04-01 |
2015-11-17 |
Idenix Pharmaceuticals Llc |
2′,4′-fluoro nucleosides for the treatment of HCV
|
US20180200280A1
(en)
|
2013-05-16 |
2018-07-19 |
Riboscience Llc |
4'-Fluoro-2'-Methyl Substituted Nucleoside Derivatives as Inhibitors of HCV RNA Replication
|
WO2014193663A1
(en)
|
2013-05-16 |
2014-12-04 |
Riboscience Llc |
4'-azido, 3'-deoxy-3'-fluoro substituted nucleoside derivatives
|
NZ714927A
(en)
|
2013-05-16 |
2020-09-25 |
Riboscience Llc |
4’-fluoro-2’-methyl substituted nucleoside derivatives
|
WO2014197578A1
(en)
|
2013-06-05 |
2014-12-11 |
Idenix Pharmaceuticals, Inc. |
1',4'-thio nucleosides for the treatment of hcv
|
EP3027636B1
(de)
|
2013-08-01 |
2022-01-05 |
Idenix Pharmaceuticals LLC |
D-amino acid phosphoramidate pronucleotide of halogenierte pyrimidine verbindungen für leber krankheiten
|
CA2921082A1
(en)
*
|
2013-08-14 |
2015-02-19 |
Rqx Pharmaceuticals, Inc. |
Linear peptide antibiotics
|
PT3038601T
(pt)
|
2013-08-27 |
2020-06-30 |
Gilead Pharmasset Llc |
Formulação combinada de dois compostos antivirais
|
EP3046924A1
(de)
|
2013-09-20 |
2016-07-27 |
IDENIX Pharmaceuticals, Inc. |
Inhibitoren des hepatitis-c-virus
|
WO2015061683A1
(en)
|
2013-10-25 |
2015-04-30 |
Idenix Pharmaceuticals, Inc. |
D-amino acid phosphoramidate and d-alanine thiophosphoramidate pronucleotides of nucleoside compounds useful for the treatment of hcv
|
WO2015065817A1
(en)
|
2013-10-30 |
2015-05-07 |
Merck Sharp & Dohme Corp. |
Pseudopolymorphs of an hcv ns5a inhibitor and uses thereof
|
WO2015066370A1
(en)
|
2013-11-01 |
2015-05-07 |
Idenix Pharmaceuticals, Inc. |
D-alanine phosphoramidate pronucleotides of 2'-methyl 2'-fluoro guanosine nucleoside compounds for the treatment of hcv
|
EP3074399A1
(de)
|
2013-11-27 |
2016-10-05 |
Idenix Pharmaceuticals LLC |
2'-dichlor- und 2'-fluor-2'-chlor-nukleosidanaloga für hcv-infektion
|
US10683321B2
(en)
|
2013-12-18 |
2020-06-16 |
Idenix Pharmaceuticals Llc |
4′-or nucleosides for the treatment of HCV
|
EP2899207A1
(de)
|
2014-01-28 |
2015-07-29 |
Amikana.Biologics |
Neues Verfahren zum Testen von HCV-Proteasehemmung
|
WO2015134780A1
(en)
|
2014-03-05 |
2015-09-11 |
Idenix Pharmaceuticals, Inc. |
Solid prodrug forms of 2'-chloro-2'-methyl uridine for hcv
|
WO2015134561A1
(en)
|
2014-03-05 |
2015-09-11 |
Idenix Pharmaceuticals, Inc. |
Pharmaceutical compositions comprising a 5,5-fused heteroarylene flaviviridae inhibitor and their use for treating or preventing flaviviridae infection
|
WO2015134560A1
(en)
|
2014-03-05 |
2015-09-11 |
Idenix Pharmaceuticals, Inc. |
Solid forms of a flaviviridae virus inhibitor compound and salts thereof
|
EP3131914B1
(de)
|
2014-04-16 |
2023-05-10 |
Idenix Pharmaceuticals LLC |
3'-substituierte methyl- oder alkynylnukleoside zur behandlung von hcv
|
RU2761476C2
(ru)
|
2015-11-20 |
2021-12-08 |
АрКьюИкс ФАРМАСЬЮТИКЭЛС, ИНК. |
Макроциклические антибиотики широкого спектра действия
|
JP7076438B2
(ja)
|
2016-06-21 |
2022-05-27 |
オリオン・オフサルモロジー・エルエルシー |
脂肪族プロリンアミド誘導体
|
WO2017222914A1
(en)
|
2016-06-21 |
2017-12-28 |
Inception 4, Inc. |
Carbocyclic prolinamide derivatives
|
EP3472149B1
(de)
|
2016-06-21 |
2023-08-30 |
Orion Ophthalmology LLC |
Heterocyclische prolinamidderivate
|
CN109661389A
(zh)
*
|
2016-08-23 |
2019-04-19 |
豪夫迈·罗氏有限公司 |
作为htra1抑制剂的新型二氟酮酰胺衍生物
|
ES2870106T3
(es)
|
2017-05-05 |
2021-10-26 |
Zealand Pharma As |
Moduladores de la comunicación intercelular de uniones comunicantes y su uso para el tratamiento de la enfermedad del ojo diabético
|
GB2563396B
(en)
|
2017-06-12 |
2020-09-23 |
Ustav Organicke Chemie A Biochemie Av Cr V V I |
Inhibitors of Rhomboid Intramembrane Proteases
|
EP3684374A4
(de)
|
2017-09-21 |
2021-06-16 |
Riboscience LLC |
4'-fluor-2'-methyl-substituierte nukleosidderivate als hemmer der hcv-rna-replikation
|
EP3891508A1
(de)
|
2018-12-04 |
2021-10-13 |
Bristol-Myers Squibb Company |
Analyseverfahren unter verwendung einer kalibrierungskurve in einer probe durch mehrfache isotopologenreaktionsüberwachung
|
CN114007605B
(zh)
|
2019-05-28 |
2022-07-15 |
豪夫迈·罗氏有限公司 |
大环广谱抗生素
|